To assess whether DR3 could be differentially expressed in prognostic classes of CLL patients, induced DR3 expression was evaluated in relation to clinical staging (according to Rai or Binet classification), standard molecular prognostic markers (IGHV, CD38 or ZAP-70 status), or cytogenetics. This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.